MCD pharma market value in seven countries to increase to $6.4 bn by 2022: GlobalData

The microvascular complications of diabetes (MCD) pharmaceutical market value in the seven major countries (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) is expected to increase from $3.6 billion in 2012 to $6.4 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 5.8 per cent, says research and consulting firm GlobalData.

The company’s latest report states that out of the 7MM, the US will show the highest growth in the MCD treatment market, with its total value jumping from $1.8 billion in 2012 to $3.7 billion by 2022, at a CAGR of 7.3 per cent. The US will be followed by the five European countries, with their combined market values expected to increase from $777 million in 2012 to $1.3 billion by 2022, at a CAGR of 5.4 per cent.

Valentina Gburcik, GlobalData’s Analyst covering Cardiovascular and Metabolic Disorders, says, “America’s rapid MCD market growth is due to the rising overall prevalence of type II diabetes in the country, thanks to its skyrocketing obesity epidemic, which is resulting in the subsequent increase in diabetic complications.”

GlobalData anticipates that the launch of AbbVie’s atrasentan in 2018 will further boost global diabetic nephropathy treatment sales, which are expected to reach $1.8 billion by 2022. Additionally, the diabetic retinopathy and neuropathy therapeutics market values are also expected to increase by the end of the forecast period, reaching $2.7 billion and $1.8 billion, respectively.

Gburcik continues, “The approval of Lucentis and Eylea for diabetic macular edema in 2012 and 2014, respectively, will overtake the patient share from the much cheaper off-label Avastin, which will drive the diabetic retinopathy market during the forecast period.

“On the other hand, the only driver behind the diabetic neuropathy market, besides the prevalence of the disease, will be a slow increase in opioid consumption by 2017, as the arena is being overtaken by generic drugs.”

Despite the success of the MCD pharmaceutical market, Gburcik says that the current therapies still leave a very high number of unmet needs.

EP News Bureau – Mumbai